- Home
- NAC vs IMCR Comparison
NAC vs IMCR Comparison
Compare NAC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAC | IMCR |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | France | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAC | IMCR |
|---|---|---|
| Price | $11.90 | $36.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 307.3K | ★ 338.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | N/A | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $9.32 | $23.15 |
| 52 Week High | $11.21 | $40.72 |
Technical Indicators
Market Signals| Indicator | NAC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 49.05 |
| Support Level | $11.85 | $35.35 |
| Resistance Level | $12.02 | $40.71 |
| Average True Range (ATR) | 0.08 | 1.82 |
| MACD | 0.01 | -0.45 |
| Stochastic Oscillator | 59.68 | 22.55 |
Price Performance
Historical ComparisonAbout NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.